Importer & Manufacturer | Source: State FDA Hyderabad

Published On: 23-04-2026

Enforcement Date: 23 April, 2026

Press Note – 23-04-2026 – Special Enforcement Drive – Weight Loss Drugs

The Drugs Control Administration (DCA), Telangana conducted a state-wide enforcement drive on 23 April 2026 targeting weight loss drugs such as Tirzepatide (Mounjaro) and Semaglutide (Ozempic, Wegovy, Rybelsus). Inspections revealed violations in 75 medical shops, leading to the issuance of show cause notices. The authority also issued a public advisory stressing prescription-only use and warning against illegal or unregulated procurement.

The Drugs Control Administration (DCA), Telangana, carried out a special enforcement drive across the State focusing on high-demand weight loss drugs, including Tirzepatide (Mounjaro) and Semaglutide-based products (Ozempic, Wegovy, Rybelsus), along with their generic equivalents.

Key points include:

The drive aimed to detect spurious and counterfeit products and ensure compliance with regulations governing their sale.
Inspections conducted at multiple medical shops revealed non-compliance in 75 establishments, including sale without valid prescriptions, absence of registered pharmacists, improper record-keeping, and failure to maintain invoices.
Show Cause Notices have been issued under the Drugs and Cosmetics Act, 1940.
The DCA also issued a public advisory emphasising that these drugs must be used strictly under specialist supervision and should not be procured through unauthorized channels or self-medicated.